Adverse outcomes of long-term use of proton pump inhibitors: A systematic review and meta-analysis

European Journal of Gastroenterology and Hepatology

Volumn 30, Issue 12, 2018, Pages 1395-1405

  Islam, Md Mohaimenul ^a   Poly, Tahmina N ^a   Walther, Bruno A ^a   Dubey, Navneet K ^a   Anggraini Ningrum, Dina N ^a,b   Shabbir, Syed Abdul ^a   Li, Yu Chuan ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b UNIVERSITAS NEGERI SEMARANG   (Indonesia)

Author keywords

Alzheimer; cancer; cardiac disease; gastroesophageal reflux disease; kidney disease; proton pump inhibitors

Indexed keywords

PROTON PUMP INHIBITOR;

ADVERSE DRUG REACTION; ADVERSE OUTCOME; ALZHEIMER DISEASE; ANEMIA; BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR RISK; COLORECTAL CANCER; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; DRUG USE; FOLLOW UP; HEART DISEASE; HIP FRACTURE; HUMAN; KIDNEY DISEASE; LONG TERM CARE; META ANALYSIS; ODDS RATIO; OUTCOME ASSESSMENT; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; COLORECTAL TUMOR; COMMUNITY ACQUIRED INFECTION; PNEUMONIA; PROCEDURES; RISK ASSESSMENT;

COLORECTAL NEOPLASMS; COMMUNITY-ACQUIRED INFECTIONS; HIP FRACTURES; HUMANS; PNEUMONIA; PROTON PUMP INHIBITORS; RISK ASSESSMENT;

EID: 85054716076     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000001198     Document Type: Review

References (133)

1. Dent J, El-Serag H, Wallander MA, Johansson S Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54:710-717.
2. Mohiuddin MK, Chowdavaram S, Bogadi V, Prabhakar B, Rao KPR, Devi S, Mohan V. Epidemic trends of upper gastrointestinal tract abnormalities: hospital-based study on endoscopic data evaluation. Asian Pac J Cancer Prev 2015; 16:5741-5747.
3. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1383-1391.
4. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101:2128-2138.
5. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008; 28:2.
6. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012; 5:219-232.
7. Eid SM, Boueiz A, Paranji S, Mativo C, RL BA, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010; 49:2561-2568.
8. Shin J, Besancon M, Prinz C, Simon A, Sachs G. Continuing development of acid pump inhibitors: site of action of pantoprazole. Aliment Pharmacol Ther 1994; 8:11-23.
9. Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000; 50:366-372.
10. Ramsay EN, Pratt NL, Ryan P, Roughead EE. Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. BMC Med Res Methodol 2013; 13:1.
11. Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 2015; 10:e0124653.
12. Lazarus B, Chen Y, Wilson F, Sang Y, Chang A, Coresh J, Grams M. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016; 176:238-246.
13. Dutertre J, Soutif D, Jonville A, Cadenne M, Valat J, Autret E. Sexual disturbances during omeprazole therapy. Lancet 1991; 338:1022.
14. Kraus A, Flores-Suárez L. Acute gout associated with omeprazole. Lancet 1995; 345:461-462.
15. Tsukamoto H, Mizoshita T, Sasaki M, Mizushima T, Tanida S, Ozeki K, et al. Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach. Asian Pac J Cancer Prev 2011; 12:1049-1054.
16. Garrote F, Lacambra C, Del Ser T, Diaz BG, Obeso G, Solis J. Subacute myopathy during omeprazole therapy. Lancet 1992; 340:672.
17. Beutler M, Hartmann K, Kuhn M, Gartmann J. Arthralgias and omeprazole. BMJ 1994; 309:1620.
18. Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf 2013; 4:125-133.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-W94.
20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283:2008-2012.
21. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev 2014; 29:MR000034.
22. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015; 8:2-10.
23. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9:1-30.
24. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
26. Moberg LM, Nilsson PM, Samsioe G, Borgfeldt C. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 2014; 78:310-315.
27. Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. Proton-pump inhibitor use and hip fractures in men: a population-based casecontrol study. Ann Epidemiol 2014; 24:286-290.
28. Reyes C, Formiga F, Coderch M, Hoyo J, Ferriz G, Casanovas J, et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone 2013; 52:557-561.
29. Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt B, Leufkens H, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2011; 22:903-910.
30. Freedberg D, Haynes K, Denburg M, Zemel B, Leonard M, Abrams J, Yang YX. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int 2015; 26:2501-2507.
31. Ding J, Heller DA, Ahern FM, Brown TV. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int 2014; 94:597-607.
32. Lee J, Youn K, Choi NK, Lee JH, Kang D, Song HJ, Park BJ. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 2013; 48:1016-1022.
33. Chiu HF, Huang YW, Chang CC, Yang CY. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010; 19:1131-1136.
34. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296:2947-2953.
35. Elaine WY, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008; 83:251-259.
36. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139:93-101.
37. Cea Soriano L, Ruigómez A, Johansson S, García Rodríguez LA. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy 2014; 34:570-581.
38. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, Wedzicha JA. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012; 106:1124-1133.
39. Almirall J, Bolibar I, Serra-Prat M, Roig J, Carandell E, Agustí M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 2008; 31:1274-1284.
40. Rodríguez LAG, Ruigómez A, Wallander M-A, Johansson S. Acidsuppressive drugs and community-acquired pneumonia. Epidemiology 2009. 800-806.
41. Hermos JA, Young MM, Fonda JR, Gagnon DR, Fiore LD, Lawler EV. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis 2012; 54:34-42.
42. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167:950-955.
43. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955-1960.
44. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149:391-398.
45. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010; 19:792-802.
46. Siersema PD, Yu S, Sahbaie P, Steyerberg EW, Simpson PW, Kuipers EJ, Triadafilopoulos G. Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use. Gastrointest Endosc 2006; 63:581-586.
47. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133:748-754.
48. Van Soest EM, van Rossum LG, Dieleman JP, van Oijen MG, Siersema PD, Sturkenboom MC, Kuipers EJ. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103:966-973.
49. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT. Proton pump inhibitor use and risk of colorectal cancer: a populationbased, case-control study. Gastroenterology 2007; 133:755-760.
50. Bradley M, Murray L, Cantwell M, Hughes C. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study. Br J Cancer 2012; 106:233-239.
51. Lai SW, Sung FC, Lin CL, Liao KF. Use of proton pump inhibitors correlates with increased risk of pancreatic cancer: a case-control study in Taiwan. Kuwait Med J 2014; 46:44-48.
52. Rodriguez LG, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case-control study in the UK. Gut 2006; 55:1538-1544.
53. Tamim H, Duranceau A, Chen LQ, LeLorier J. Association between use of acid-suppressive drugs and risk of gastric cancer. Drug Saf 2008; 31:675-684.
54. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int 2014; 86:837-844.
55. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol 2013; 14:1.
56. Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open 2015; 3:E166.
57. Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, Bilker WB, et al. Proton pump inhibitors and traditional nonsteroidal antiinflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 2012; 21:1155-1172.
58. Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, Franco OH, Kuipers EJ, Hofman A, et al. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis 2015; 66:775-782.
59. Zipursky J, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Paterson JM, et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. PLoS Med 2014; 11:e1001736.
60. Luk CP, Parsons R, Lee YP, Hughes JD. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 2013; 47:773-780.
61. Markovits N, Loebstein R, Halkin H, Bialik M, Landes-Westerman J, Lomnicky J, Kurnik D. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol 2014; 54:889-895.
62. Lindner G, Funk GC, Leichtle AB, Fiedler G, Schwarz C, Eleftheriadis T, et al. Impact of proton pump inhibitor use on magnesium homoeostasis: a cross-sectional study in a tertiary emergency department. Int J Clin Pract 2014; 68:1352-1357.
63. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol 2014; 177:292-297.
64. Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010; 153:378-386.
65. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57:422-428.
66. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013; 310:2435-2442.
67. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol 2016; 73:410-416.
68. Bax JJ, Delgado V. Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol 2015; 22:229-245.
69. CDC, NCHS. Underlying Cause of Death 1999-2013 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999-2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Available at: https://www.cdc.gov/heart disease/facts.htm. [Accessed 3 February 2015].
70. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on adolescent drug use: overview of key findings, 2011. Instit Soc Res 2003; 2:213-233.
71. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. An unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor ADMA. Circulation 2013; 113:003602.
72. Chyrchel B, Chyrchel M, Surdacki A. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2014; 129:e425-e425.
73. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013; 80:1778-1783.
74. Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement 2015; 11:332.
75. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
76. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 2015; 314:1818-1830.
77. Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis 2010; 19:573-589.
78. Badiola N, Alcalde V, Pujol A, Münter LM, Multhaup G, Lleó A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One 2013; 8:e58837.
79. Fallahzadeh M, Borhani Haghighi A, Namazi M. Proton pump inhibitors: predisposers to Alzheimer disease? J Clin Pharm Ther 2010; 35:125-126.
80. De Benoist B, McLean E, Egli I, Cogswell M. Worldwide prevalence of anaemia 1993-2005 WHO Global Database on Anaemia. Geneva: World Health Organization; 2008.
81. Powers A, Silberstein L. Autoimmune hemolytic anemia Hematology: basic principles and practice, 5th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2008.
82. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011; 56:2349-2353.
83. Jayathilakan K, Sultana K, Radhakrishna K, Bawa AS. Utilization of byproducts and waste materials from meat, poultry and fish processing industries: a review. J Food Sci Technol 2012; 49:278-293.
84. Kwak CS, Lee MS, Lee HJ, Whang JY, Park SC. Dietary source of vitamin B12 intake and vitamin B12 status in female elderly Koreans aged 85 and older living in rural area. Nutr Res Pract 2010; 4:229-234.
85. Ruscin JM, Page RL, Valuck RJ. Vitamin B12 deficiency associated with histamine 2-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 2002; 36:812-816.
86. Whang R, Ryder KW. Frequency of hypomagnesemia and hypermagnesemia: requested vs routine. JAMA 1990; 263:3063-3064.
87. Marx J, Walls R, Hockberger R. Rosen's emergency medicineconcepts and clinical practice. Saunders, USA: Elsevier Health Sciences; 2013.
88. Elisaf M, Merkouropoulos M, Tsianos E, Siamopoulos K. Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. J Trace Elem Med Biol 1995; 9:210-214.
89. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Silver Spring, MD: US Food and Drug Administration; 2011.
90. Danziger J, William JH, Scott DJ, Lee J, Lehman LW, Mark RG, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013; 83:692-699.
91. Schenk B, Festen H, Kuipers E, Klinkenberg-Knol E, Meuwissen S. Effect of short-and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996; 10:541-545.
92. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56:S11-S17.
93. Scholl S, Dellon ES, Shaheen NJ. Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions. Am J Gastroenterol 2011; 106:386-392.
94. Martin R, Lim A, Kelly S, Hilton S. H2 receptor antagonists and proton pump inhibitors in general practice: prescribing trends in the UK from 1991 to 1996. Gut 1997; 40:F237-F237.
95. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317:452-456.
96. Pallarito K. How safe are popular reflux drugs? Experts debate evidence linking acid-blockers to possible bone, heart problems. US News World Rep 2009.
97. Nasser SC, Slim M, Nassif JG, Nasser SM. Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes. World J Gastroenterol 2015; 21:4599.
98. Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficileassociated diarrhea. World J Gastroenterol 2010; 16:3573-3577.
99. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170:772-778.
100. Dalton B, Lye-Maccannell T, Henderson E, Maccannell D, Louie T. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther 2009; 29:626-634.
101. Turco R, Martinelli M, Miele E, Roscetto E, Del Pezzo M, Greco L, Staiano A. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010; 31:754-759.
102. Dial S, Delaney J, Barkun AN, Suissa S. Use of gastric acidsuppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989-2995.
103. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013; 108:1794-1801.
104. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000; 95:3118-3122.
105. Naunton M, Peterson G, Bleasel M. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25:333-340.
106. Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci 2006; 28:189-193.
107. Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, Bianchi Porro G. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther 2003; 17:1503-1506.
108. Walker N, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001; 23:116-117.
109. Mat Saad A, Collins N, Lobo M, O'Connor H. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 2005; 59:31-34.
110. Jarchow-MacDonald AA, Mangoni AA. Prescribing patterns of proton pump inhibitors in older hospitalized patients in a Scottish health board. Geriatr Gerontol Int 2013; 13:1002-1009.
111. Chen CH, Lin HC, Lin HL, Lin YT, Chou JM, Hsu SP, Fung CP. Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease. J Microbiol Immunol Infect 2015; 46:390-396.
112. Ho SW, Tsai MC, Teng YH, Yeh YT, Wang YH, Yang SF, Yeh CB. Population-based cohort study on the risk of pneumonia in patients with non-traumatic intracranial haemorrhage who use proton pump inhibitors. BMJ Open 2014; 4:e006710.
113. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 2004; 171:33-38.
114. Ortolani P, Marino M, Marzocchi A, De Palma R, Branzi A. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. J Cardiovasc Med (Hagerstown) 2012; 13:783-789.
115. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors: where do we stand in 2012. World J Gastroenterol 2012; 18:2161-2171.
116. Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 2011; 4:365-380.
117. Mohammad A, Brilakis ES, Weideman RA, Little BB, Banerjee S. The clinical relevance of the clopidogrel-proton pump inhibitor interaction. J Cardiovasc Transl Res 2012; 5:547-552.
118. Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 2012; 32:809-818.
119. Hak E, Mulder B, Schuiling-Veninga CC, de Vries TW, Jick SS. Use of acid-suppressive drugs in pregnancy and the risk of childhood asthma: bidirectional crossover study using the general practice research database. Drug Saf 2013; 36:1097-1104.
120. Schoenfeld JD, Ioannidis JP. Is everything we eat associated with cancer? a systematic cookbook review. Am J Clin Nutr 2012; 97:127-134.
121. Elaine WY, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124:519-526.
122. Chen CH, Lin CL, Kao CH. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int 2016; 27:2117-2126.
123. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138:896-904.
124. Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107:1361-1369.
125. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010; 170:765-771.
126. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? a meta-analysis. Expert Rev Clin Pharmacol 2012; 5:337-344.
127. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015; 10:e0128004.
128. Lee SW, Lin CH, Lien HC, Lee TY, Yeh HZ, Chang CS. Proton pump inhibitors did not increase risk of pneumonia in patients with chronic obstructive pulmonary disease. J Clin Med Res 2015; 7:880.
129. Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with metaanalysis. Gut 2014; 63:552-558.
130. Koulouridis I, Alfayez M, Tighiouart H, Madias NE, Kent DM, Paulus JK, Jaber BL. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis 2013; 62:730-737.
131. Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf 2011; 20:1043-1049.
132. Lin CF, Shen LJ, Wu FLL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol 2012; 74:824-834.
133. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152:337-345